Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kevin Grogan

Managing Editor

London, UK

Kevin Grogan has been writing about pharmaceuticals for over twenty years in roles that have included online editor for PharmaTimes. After four years freelancing, which involved writing for all the principal titles in the sector, as well as consultancy work with major pharmaceutical companies, he joined Scrip as Managing Editor, Europe, Commercial in the summer of 2017.

Covering all aspects of the pharma industry, Kevin has interviewed pretty much all the leading figures in the sector, both in the UK and globally. A regular attendee at financial and medical conferences worldwide (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss events in the pharmaceutical industry.

Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at the Catholic weekly newspaper The Universe and also contributed articles to the likes of The Independent and the Manchester Evening News on football.

Advertisement
Set Alert for Articles By Kevin Grogan

Latest From Kevin Grogan

Interview: Akari's Coversin Ticking Along Nicely

The C5 complement inhibitor class is in the news following UCB's bid for Ra Pharmaceuticals. Akari's CEO tells Scrip he thinks Coversin, which inhibits leukotriene B4 as well as C5, may offer more benefits in certain orphan diseases.

Rare Diseases Inflammation

UCB To Buy Ra for $2.1bn And Plays Down Antitrust Fears

The deal, welcomed by analysts, means that the Belgian drug maker has two late-stage products for the rare disease myasthenia gravis to challenge Alexion's Soliris.
M & A Companies

Mixed Data For Merck KGaA's Disease-Modifying OA Drug

Sprifermin could be the first drug to affect the underlying disease process in osteoarthritis but data show no significant improvement in symptoms.
Inflammation Clinical Trials

Interview: An EU Plan To Pair Pharma With Life Science VCs

Jan-Philipp Beck, CEO of EIT Health, believes a link-up with the European Investment Fund can only benefit the continent's biotech ecosystem.

Europe Commercial

J&J Pledges $500m To Eliminate HIV and TB

The healthcare giant is investing heavily into partnerships designed to beat the two infectious diseases.

Companies Clinical Trials

AstraZeneca Gains US OK For Fasenra In Patient-Friendly Form

The company is keeping up the pressure on GSK, getting approval for self-administration for Fasenra a few months after a similar green light for severe asthma rival Nucala.

Respiratory Approvals
See All
Advertisement
UsernamePublicRestriction

Register